Announcement under Regulation 30 (LODR)-Allotment
Filed with BSE · ISIN INE194R01017 · · 4 pages · English
Re: Allotment of 1,82,400 Equity Shares to Non-Promoter Allottees pursuant to conversion of 60,800 Warrants into Equity Shares, consequent to the 1:2 Bonus Issue. This is to inform you that Board of Directors of the Company had pursuant to the approval of Shareholders in their Extra-Ordinary General Meeting held on October 22, 2025, had allotted convertible warrants on preferential basis to Allott
Fredun Pharmaceuticals Ltd. on 6ix
Earlier from Fredun Pharmaceuticals
- Revised Outcome Of Board Meeting Dated 03Rd October, 2026.
- Board Meeting Outcome for Allotment Of 1,82,400 Equity Shares To Non-Promoter Allottees Pursuant To Conversion Of 60,800 Warrants Into Equity Shares, Consequent To The 1: 2 Bonus Issue.
- Fredun Pharmaceuticals Ltd. Press Release Sep 22 2026
- Fredun Pharmaceuticals Ltd. Press Release Sep 15 2026
- Fredun Pharmaceuticals Ltd. Press Release Sep 08 2026
Later from Fredun Pharmaceuticals
- Announcement under Regulation 30 (LODR)-Press Release / Media Release
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
- Board Meeting Outcome for Outcome Of The Board Meeting
- Financial Results For The Quarter Ended 30Th September, 2026.
- Approved The Proposal For Making An Application To National Stock Exchange Of India Limited (NSE) For Listing And Trading Of The Equity Shares Of The Company On NSE.
Follow Fredun Pharmaceuticals into a list and get an email when it puts out news.
Follow Fredun Pharmaceuticals